Logo Logo Logo Logo Logo
  • About Us
    • Our Mission
    • About Odylia
    • Our Board
    • Our Team
  • Our Impact
    • Odylia Impact Report
    • Newsletter
    • News
  • Support Odylia
    • Donate
    • Other ways to Give
    • Change for A Cure
    • Getting Involved
  • Pipeline & Services
    • Odylia Pipeline & Services Overview
    • Odylia Pipeline
      • RPGRIP1 Gene Therapy
      • USH1C Gene Therapy
    • Brydge Solutions
    • Anc80 Resources
  • Resources
    • The Odylia Library
    • The Odylia Collective
    • Rare Disease Resources
    • Fundraising Resources
    • Webinars and Presentations
  • Donate
  • About Us
    • Our Mission
    • About Odylia
    • Our Board
    • Our Team
  • Our Impact
    • Odylia Impact Report
    • Newsletter
    • News
  • Support Odylia
    • Donate
    • Other ways to Give
    • Change for A Cure
    • Getting Involved
  • Pipeline & Services
    • Odylia Pipeline & Services Overview
    • Odylia Pipeline
      • RPGRIP1 Gene Therapy
      • USH1C Gene Therapy
    • Brydge Solutions
    • Anc80 Resources
  • Resources
    • The Odylia Library
    • The Odylia Collective
    • Rare Disease Resources
    • Fundraising Resources
    • Webinars and Presentations
  • Donate

Odylia Newsletter

Stay up-to-date on the latest news from Odylia by signing-up for our newsletter today.

Sign-up

March 2024 Newsletter

July 2024 Newsletter

October 2024 Newsletter

March 2023 Newsletter

July 2023 Newsletter

October 2023 Newsletter

March 2022 Newsletter

September 2022 Newsletter

March 2021 Newsletter

September 2021 Newsletter

Questions? We’re here to help!

Contact Us
Services
  • Odylia Pipeline & Services Overview
  • Brydge Solutions

Visit Odylia's linked in page Visit Odylia's linked in page

Science
  • Research and Development
  • Our Mission
Resources
  • The Odylia Library
  • The Odylia Collective
  • Resources
  • Webinars and Presentations
  • Clinical Trials
Latest News
  • Comend and Odylia Partner to Advance Rare Disease Drug Development with Innovative Patient-Driven Platform
  • Odylia Therapeutics Announces New Pipeline Project: A Gene Replacement Therapy for NPHP1 Retinal Dystrophy
  • Odylia Therapeutics drives commitment to rare disease drug development through Rare Disease Day event
Odylia Therapeutics logo

© 2025 Odylia Therapeutics | Registered 501(c)(3). EIN: 82-2120760 | Site by Hester Designs